title: Plasma levels of copeptin in patients with coronary heart disease.
abstract: The present study was undertaken to investigate alteration in plasma levels of copeptin, a stable fragment derived from provasopressin, in patients with coronary heart disease. We measured plasma level of copeptin in 21 patients with coronary heart disease (CHD) and 12 age-matched healthy subjects by radioimmunoassay (RIA). Chi-square test, Student's t-test and one-way analysis of variance were used for statistical analyses. Correlations between variables were tested by simple linear regression analysis. The plasma level of copeptin was significantly increased in patients (43.07 +/- 17.08 vs 11.13 +/- 5.73 pmol/l in controls, P < 0.01) and was further increased, by 60%, to 68.71 +/- 16.81 pmol/l on day 1 after therapy with percutaneous transluminal coronary angioplasty (PTCA) and stent (P < 0.05). On days 3 and 7 after therapy, the levels were greatly decreased, to 38.82 +/- 19.00 and 32.10 +/- 14.00 pmol/l, respectively, from that before therapy (all P < 0.05) but were higher, by 249% and 188%, respectively, than that of controls (all P < 0.01). The results suggest that the vasopressin system is activated in patients with CHD as indicated by changes in copeptin level, especially after PTCA and stent therapy. As a potential risk factor for CHD, plasma copeptin activation might have important clinical significance in terms of early intervention in patients with CHD.
authors.affiliation: Department of Cardiovascular Disease, Beijing Fengtai Hospital, Beijing, PR China. chaisb@126.com
authors.forename: San Bao
authors.initials: SB
authors.lastname: Chai
authors.forename: Yong Ming
authors.initials: YM
authors.lastname: Hui
authors.forename: Xue Min
authors.initials: XM
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiao
authors.forename: Chao Shu
authors.initials: CS
authors.lastname: Tang